Core Viewpoint - Galaxy Digital Inc. (GLXY) has shown a significant price increase of 42.1% over the past four weeks, with a mean price target of $48.63 indicating a potential upside of 52% from the current trading price of $31.99 [1] Price Targets and Analyst Estimates - The mean estimate consists of 14 short-term price targets with a standard deviation of $9.06, suggesting variability in analyst predictions. The lowest estimate is $24.00 (25% decline), while the highest is $60.00 (87.6% increase) [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts are optimistic about GLXY's earnings prospects, as indicated by a positive trend in earnings estimate revisions. The Zacks Consensus Estimate for the current year has increased by 28.5% over the last 30 days, with one estimate moving higher and no negative revisions [11][12] - GLXY holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, which supports the stock's potential upside in the near term [13] Caution on Price Targets - While price targets are often sought after by investors, they can be misleading. Empirical research shows that price targets rarely indicate the actual direction of a stock's price [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Day One Biopharmaceuticals, Inc. (DAWN) has seen a 22.5% increase in share price over the past four weeks, closing at $10.73, with a mean price target of $22.25 indicating a potential upside of 107.4% according to Wall Street analysts [1]. Price Targets and Analyst Estimates - The mean estimate consists of eight short-term price targets with a standard deviation of $4.86, where the lowest estimate of $16.00 suggests a 49.1% increase, and the highest estimate of $29.00 indicates a potential surge of 170.3% [2]. - A low standard deviation signifies a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9]. Earnings Estimates and Analyst Optimism - Analysts are optimistic about DAWN's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which has shown a strong correlation with near-term stock price movements [11]. - The Zacks Consensus Estimate for the current year has increased by 20.6% over the past month, with one estimate rising and no negative revisions [12]. - DAWN holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13]. Caution on Price Targets - While price targets are often sought after by investors, they can mislead and should not be the sole basis for investment decisions, as empirical research indicates that they rarely predict actual stock price movements [7][10].

Core Insights - Ascendis Pharma A/S (ASND) shares increased by 3% to close at $215.05, following a notable trading volume compared to typical sessions, despite a 2.1% loss over the past four weeks [1] Group 1: Company Performance - The rise in stock price is attributed to the commercial success of Ascendis Pharma's two marketed drugs, Skytrofa and Yorvipath, which are expected to generate preliminary fourth-quarter revenues of €53 million and €187 million, respectively [2] - The company is also exploring label expansions for these drugs into additional indications [2] Group 2: Earnings Expectations - Ascendis Pharma is projected to report quarterly earnings of $0.13 per share, reflecting a year-over-year increase of 119.1%, with revenues anticipated at $287.45 million, a 54.9% increase from the previous year [3] - However, the consensus EPS estimate has been revised down by 3.9% over the last 30 days, indicating a negative trend in earnings estimate revisions, which typically does not lead to price appreciation [4] Group 3: Industry Context - Ascendis Pharma is part of the Zacks Medical - Biomedical and Genetics industry, which includes Coherus Oncology (CHRS), whose stock also saw a 3% increase, closing at $1.7, with an 18.7% return over the past month [4] - Coherus Oncology's consensus EPS estimate remains unchanged at -$0.31, representing a year-over-year decline of 10.7% [5]

Core Viewpoint - S&P Global (SPGI) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][2]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in a company's earnings picture, which is crucial for predicting near-term stock price movements [2][3]. - A strong correlation exists between earnings estimate revisions and stock price movements, largely influenced by institutional investors who adjust their valuations based on these estimates [3]. Company Performance and Outlook - The upgrade for S&P Global indicates an improvement in the company's underlying business, suggesting that investor sentiment may drive the stock price higher [4]. - For the fiscal year ending December 2025, S&P Global is expected to earn $17.71 per share, with a 3% increase in the Zacks Consensus Estimate over the past three months [7]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [6]. - The upgrade of S&P Global to a Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [9].

Core Viewpoint - PG&E (PCG) shares have shown a slight increase of 0.2% over the past four weeks, closing at $15.98, with analysts suggesting a potential upside of 33.4% based on a mean price target of $21.32 [1] Price Targets and Analyst Estimates - The mean estimate consists of 14 short-term price targets with a standard deviation of $1.54, indicating variability among analysts; the lowest estimate is $18.00 (12.6% increase), while the highest is $25.00 (56.5% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about PCG's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.1%, with one estimate moving higher and no negative revisions [12] - PCG holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential for upside [13] Caution on Price Targets - While price targets are often sought after by investors, they can mislead; empirical research shows that they rarely indicate actual stock price movements [7] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8] - Investors should approach price targets with skepticism and not rely solely on them for investment decisions [10]

Core Viewpoint - FedEx has been upgraded to a Zacks Rank 2 (Buy), indicating a positive outlook on its earnings estimates, which significantly influence stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system is based on changes in earnings estimates, which are strongly correlated with near-term stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling actions that affect stock prices [4]. FedEx's Earnings Outlook - FedEx is projected to earn $18.00 per share for the fiscal year ending May 2026, with no year-over-year change expected [8]. - Over the past three months, the Zacks Consensus Estimate for FedEx has increased by 0.4%, reflecting a positive trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 (Strong Buy) stocks historically generating an average annual return of +25% since 1988 [7]. - FedEx's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating strong potential for market-beating returns in the near term [10].

Shares of Klarna (KLAR) have gained 8.4% over the past four weeks to close the last trading session at $30.48, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $46.06 indicates a potential upside of 51.1%.The mean estimate comprises 16 short-term price targets with a standard deviation of $3.7. While the lowest estimate of $39.00 indicates a 28% increase from the current price le ...

Core Insights - Worthington Steel, Inc. reported quarterly earnings of $0.38 per share, missing the Zacks Consensus Estimate of $0.48 per share, but showing an increase from $0.19 per share a year ago, resulting in an earnings surprise of -20.83% [1] - The company posted revenues of $871.9 million for the quarter ended November 2025, exceeding the Zacks Consensus Estimate by 11.35% and up from $739 million year-over-year [2] - Worthington Steel's shares have increased by approximately 11.4% since the beginning of the year, compared to a 15.6% gain in the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.68 on revenues of $803 million, and for the current fiscal year, it is $2.72 on revenues of $3.39 billion [7] - The estimate revisions trend for Worthington Steel was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Steel - Specialty industry, to which Worthington Steel belongs, is currently ranked in the top 15% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Core Viewpoint - Mitek Systems (MITK) has shown a significant price increase of 11.6% over the past four weeks, with a mean price target of $13 indicating a potential upside of 34.7% from the current price of $9.65 [1] Price Targets and Estimates - The average price target consists of four short-term estimates ranging from a low of $10.00 to a high of $15.00, with a standard deviation of $2.16, indicating variability among analysts [2] - The lowest estimate suggests a 3.6% increase, while the highest indicates a 55.4% upside potential [2] - A low standard deviation signifies greater agreement among analysts regarding price movement [9] Analyst Sentiment and Earnings Estimates - Analysts are optimistic about MITK's earnings prospects, as indicated by a consensus that suggests better earnings than previously estimated [4] - Over the last 30 days, two earnings estimates have been revised upward, leading to a 1.9% increase in the Zacks Consensus Estimate for the current year [12] - MITK holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors [13] Caution on Price Targets - While price targets are often sought after, their reliability is questioned, as they can mislead investors [3][7] - Analysts may set overly optimistic targets due to business incentives, which can inflate price expectations [8] - Despite the skepticism surrounding price targets, the direction implied by them can serve as a useful guide for further research [10][14]

Core Viewpoint - OR Royalties (OR) has shown an 8.8% increase in stock price over the past four weeks, with a mean price target of $43.4 indicating a potential upside of 25% from the current price of $34.71 [1] Price Targets and Analyst Estimates - The mean estimate consists of 11 short-term price targets with a standard deviation of $6.7, where the lowest estimate is $37.06 (6.8% increase) and the highest is $61.92 (78.4% increase) [2] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Market Sentiment - Analysts have shown increasing optimism about OR's earnings prospects, with a positive trend in earnings estimate revisions indicating potential upside [11] - Over the last 30 days, one estimate has increased, leading to a 1.2% rise in the Zacks Consensus Estimate for the current year [12] - OR holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are often sought after, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8] - Investors should treat price targets with skepticism and not rely solely on them for investment decisions [10]